: 免疫检查点抑制剂开启了肿瘤治疗的新时代, 但随着临床应用的增加, 免疫治疗相关不良反应亦
不断被报道并逐渐引发关注. 肝毒性是其中较常发生且具有一定致死性的严重不良反应, 及早…

… of liver injury, related risk factors, and incidence rate and summarizes the treatment methods
for liver injury … non-homogeneous immune-related liver injury due to the specificity of non-…

… Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with
… Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with …

… -induced liver injury,DILI),简 称为ICI 相关性肝损伤(immune-mediated liver injury caused by
… Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with …

… focusing on the field of immunotherapy-related research. … B cell landscape in human
hepatocellular carcinoma (HCC) in … non-tumor liver tissues, obtaining results which were then …

… Results: A total of 166 patients received 910 times of treatment, with an average of 5.48
times of immune checkpoint inhibitor treatment. A total of 146 cases had adverse events of …

… Risk of HBV reactivation in patients with immune checkpoint inhibitor -treated unresectable
hepatocellular carcinoma [ J ]. J Immunother Cancer, 2020, 8(2): e001072. DOI: 10. …

… hepatotoxicity, IMH)是一类较常见的irAE,在很多情况下,人们更多 关注的是肝细胞型IMH(hepatocellular …
of suspected immunemediated liver injury caused by immune checkpoint inhibitors …

… [Abstract] This article reports a case of a 55-year-old male patient who received camrelizumab
due to poorly differentiated hepatocellular carcinoma. Two weeks later,he experienced …

… Correlation analysis of eRNA AP003469.2 and prognosis of patients with hepatocellular …
Correlation analysis of eRNA AP003469.2 and prognosis of patients with hepatocellular …